Autophagy maintains tumour growth through circulating arginine. (22nd November 2018)

• Record Type: Journal Article
• Authors: Poillet-Perez, Laura; Xie, Xiaoqi; Zhan, Le; Yang, Yang; Sharp, Daniel; Hu, Zhixian; Su, Xiaoyang; Maganti, Anurag; Jiang, Cherry; Lu, Wenyun; Zheng, Haiyan; Bosenberg, Marcus; Mehnert, Janice; Guo, Jessie; Lattime, Edmund; Rabinowitz, Joshua; White, Eileen
• Is Part Of: Nature. Volume 563:Number 7732(2018)
• Page Start: 569
• Page End: 573
• Publication Date: 2018-11-22
• Subjects: Science -- Periodicals; 505
• DOI: 10.1038/s41586-018-0697-7
• Languages: English
• ISSNs: 0028-0836

Abstract

Abstract Autophagy captures intracellular components and delivers them to lysosomes, where they are degraded and recycled to sustain metabolism and to enable survival during starvation1–5 . Acute, whole-body deletion of the essential autophagy geneAtg7 in adult mice causes a systemic metabolic defect that manifests as starvation intolerance and gradual loss of white adipose tissue, liver glycogen and muscle mass1 . Cancer cells also benefit from autophagy. Deletion of essential autophagy genes impairs the metabolism, proliferation, survival and malignancy of spontaneous tumours in models of autochthonous cancer6, 7 . Acute, systemic deletion ofAtg7 or acute, systemic expression of a dominant-negative ATG4b in mice induces greater regression of KRAS-driven cancers than does tumour-specific autophagy deletion, which suggests that host autophagy promotes tumour growth1, 8 . Here we show that host-specific deletion ofAtg7 impairs the growth of multiple allografted tumours, although not all tumour lines were sensitive to host autophagy status. Loss of autophagy in the host was associated with a reduction in circulating arginine, and the sensitive tumour cell lines were arginine auxotrophs owing to the lack of expression of the enzyme argininosuccinate synthase 1. Serum proteomic analysis identified the arginine-degrading enzyme arginase I (ARG1) in the circulation ofAtg7 -deficient hosts, and in vivo arginine metabolic tracing demonstrated that serum arginine was degraded to ornithine. ARG1 is predominantly expressed in the liver and can be released from hepatocytes into the circulation. Liver-specific deletion ofAtg7 produced circulating ARG1, and reduced both serum arginine and tumour growth. Deletion ofAtg5 in the host similarly regulated circulating arginine and suppressed tumorigenesis, which demonstrates that this phenotype is specific to autophagy function rather than to deletion ofAtg7 . Dietary supplementation ofAtg7 -deficient hosts with arginine partially restored levels of circulating arginine and tumour growth. Thus, defective autophagy in the host leads to the release of ARG1 from the liver and the degradation of circulating arginine, which is essential for tumour growth; this identifies a metabolic vulnerability of cancer. Mice with whole-body or liver-specific deletion ofAtg7 release circulating arginase I and have reduced levels of serum arginine, which impairs the growth of allografted arginine-auxotrophic tumours.